We are live on ! Find out more
AMBI

Ambit Biosciences Corp
AMBI

Delisted

AMBI was delisted on the 10th of November, 2014.

Back to rankings

49 hedge funds and large institutions have $154M invested in Ambit Biosciences Corp in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more capital invested

Capital invested by funds: $67M → $154M (+$86.5M)

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

36% more funds holding

Funds holding: 36 → 49 (+13)

Holders
49
Holders Change
+13
Holders Change %
+36.11%
% of All Funds
1.42%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
24
Increased
9
Reduced
5
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$2.37M
2
U
UBS
Switzerland
+$1.27M
3
GP
GLG Partners
United Kingdom
+$1.24M
4
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
+$1.19M
5
AQR Capital Management
AQR Capital Management
Connecticut
+$1.11M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$3.12M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.75M
3
WC
Wexford Capital
Florida
-$2.28M
4
SFM
Sphera Funds Management
Israel
-$1.92M
5
AG
Artal Group
Luxembourg
-$1.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management I
California
$32M – – –
AC
2
Aisling Capital
New York
$25.4M – – –
O
3
OrbiMed
New York
$23M – – –
BBA
4
Baker Bros. Advisors
New York
$16.8M +$2.37M +345,378 +46%
GPP
5
Great Point Partners
Connecticut
$9.24M -$3.12M -453,895 -43%
GCM
6
Gruss Capital Management
New York
$6.83M +$590K +85,826 +24%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.35M +$186K +27,098 +11%
U
8
UBS
Switzerland
$2.85M +$1.27M +184,991 New
GP
9
GLG Partners
United Kingdom
$2.77M +$1.24M +180,000 New
COPPSERS
10
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$2.66M +$1.19M +172,560 New
AQR Capital Management
11
AQR Capital Management
Connecticut
$2.48M +$1.11M +160,924 New
JP Morgan Chase
12
JP Morgan Chase
New York
$2.43M +$1.09M +158,053 New
SAM
13
Sectoral Asset Management
Quebec, Canada
$2.25M +$1M +146,111 New
LOM
14
Loeb Offshore Management
New York
$2.15M +$959K +139,510 New
WIC
15
Water Island Capital
New York
$1.95M +$869K +126,415 New
GF
16
Gabelli Funds
New York
$1.54M +$687K +100,000 New
PAMP
17
Polar Asset Management Partners
Ontario, Canada
$1.54M +$687K +100,000 New
B
18
Bailard
California
$1.43M – – –
Morgan Stanley
19
Morgan Stanley
New York
$1.36M +$484K +70,397 +392%
TL
20
TowerView LLC
New York
$1.29M +$576K +83,762 New
Macquarie Group
21
Macquarie Group
Australia
$1.18M – – –
GI
22
GAMCO Investors
Connecticut
$762K +$340K +49,500 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$696K +$69.6K +10,122 +29%
BCM
24
Bridgeway Capital Management
Texas
$695K – – –
Jane Street
25
Jane Street
New York
$682K +$304K +44,299 New
1
2 3

AMBI Hedge Fund Activity: Q3 2014 in Review

49 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q3 2014, worth a combined $154M — up 129% from $67M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AMBI positions and 11 closed out — a net gain of 13 holders — while 9 added to existing stakes and 5 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $2.37M. The largest seller was Great Point Partners, cutting an estimated $3.12M.

  • 49 institutional investors held Ambit Biosciences Corp (AMBI) as of Q3 2014, up from 36 in Q2 2014.
  • Funds reported $154M of Ambit Biosciences Corp stock for Q3 2014, up 129% quarter-over-quarter.
  • 24 funds opened new Ambit Biosciences Corp positions in Q3 2014 and 11 closed out, a net change of +13 holders.
  • The largest Ambit Biosciences Corp buyer in Q3 2014 was Baker Bros. Advisors, an estimated $2.37M added.
  • The largest Ambit Biosciences Corp seller in Q3 2014 was Great Point Partners, an estimated $3.12M sold.

Based on aggregated 13F filings for Q3 2014.